Helped discover sits at the center of this dementia and brain health question.

In March 2026, the scientific community lost Susan Henry, the pioneering molecular geneticist whose work fundamentally advanced our understanding of how cells control their fundamental processes—and how those processes go wrong in cancer. At 79, Dr. Henry left behind a legacy that has shaped decades of cancer research and continues to influence cellular biology across multiple diseases. Her definition of the “Henry Regulatory Circuit”—the mechanism cells use to determine whether lipids are deployed for growth or stored as fat—unlocked understanding that benefits not just cancer research but also obesity and diabetes science.

For readers interested in brain health and aging, Henry’s work matters because the cellular processes she illuminated affect how our cells age, how they resist disease, and ultimately how we maintain neurological function as we grow older. Dr. Henry’s passing coincides with a remarkable acceleration in cancer genetics—a field she helped pioneer. In the weeks surrounding her death, researchers announced breakthrough discoveries that show the direct line from genetic discovery to clinical breakthrough: new mapping of the CTNNB1 gene predicting tumor behavior, successful drugs finally targeting the long-considered “undruggable” KRAS mutation responsible for 25% of all cancers, and a revolutionary method to permanently silence cancer genes by targeting epigenetic proteins. These advances stand on foundations laid by scientists like Henry and her peers who asked the fundamental question: how do genes become cancer, and what can we do about it? This article explores the legacy of scientists like Susan Henry through the lens of their most lasting contributions—the genetic discoveries that have transformed cancer treatment and continue reshaping modern medicine.

Why Cancer Gene Discoveries Matter Beyond the Oncology Ward
The BRCA Discovery: From Genetic Find to Changed Lives
Breaking the “Undruggable” Barrier: KRAS and Modern Targeted Therapy
Mapping Cancer Gene Mutations: From Data to Prediction
Permanently Silencing Cancer Genes: The Epigenetic Revolution
The Pancreatic Cancer Resistance Problem: Understanding Therapy Resistance
Building on the Legacy: The Future of Genetic Medicine
Conclusion

Why Cancer Gene Discoveries Matter Beyond the Oncology Ward

When a scientist discovers a cancer gene, they are not simply identifying a disease mechanism in isolation. They are revealing something about how human cells work—knowledge that applies to aging, to neurodegeneration, and to every tissue in the body. Susan Henry’s work on cellular regulatory circuits exemplifies this: by understanding how cells decide to grow versus store resources, she illuminated pathways relevant to cancer (where growth goes wrong), obesity (where storage mechanisms misfire), and the metabolic aspects of aging (where balance breaks down).

This broad relevance explains why cancer genetics matters to people focused on brain health. The cellular mechanisms that protect against cancer—DNA repair, programmed cell death, growth control—are the same mechanisms that protect brain cells from age-related damage. A discovery that shows how to “switch off” a cancer gene in leukemia cells (as Monash and Harvard researchers did by targeting Menin or DOT1L proteins) reveals fundamental information about epigenetic control that may one day help us understand why some brains age more slowly than others. The regulatory circuits Henry studied are active in every cell type, including neurons.

Why Cancer Gene Discoveries Matter Beyond the Oncology Ward

The BRCA Discovery: From Genetic Find to Changed Lives

The clearest example of how cancer gene discovery creates lasting legacy appears in the BRCA story, which reaches a significant milestone in 2026—thirty years since Mary-Claire King discovered BRCA1 on chromosome 17q21 in 1990. That discovery revealed that mutations in this single gene could raise a woman’s lifetime breast cancer risk from the population average of 8% to over 80%. Five years later, researchers identified BRCA2, the second major hereditary breast cancer gene. Hundreds of thousands to millions of people globally have since been tested for BRCA mutations, an explosion of testing unimaginable before these genes were known.

What transforms a genetic discovery into a legacy is what happens next: the translation of knowledge into treatment. Beginning in 2005, researchers found that cancer cells carrying BRCA mutations have a critical weakness—they are vulnerable to PARP inhibitors, a new class of drugs. Today, PARP inhibitors are standard treatment for BRCA-related breast, ovarian, prostate, and pancreatic cancers. The chain from King’s discovery to today’s treatment protocols spans three decades and has saved or extended thousands of lives. However, it is important to note that not all BRCA carriers develop cancer, and testing without genetic counseling can create anxiety; the legacy includes not just treatment but also the infrastructure of genetic counseling that helps people make sense of their risk.

Breaking the “Undruggable” Barrier: KRAS and Modern Targeted Therapy

For decades, oncologists considered certain cancer genes untargetable. The KRAS gene stood as the symbol of this frustration—it drives approximately 25% of all cancerous tumors, making it statistically one of the most important cancer genes, yet for years researchers could not develop drugs that could reliably shut it down. The assumption was that KRAS proteins were too simple, too fundamental, too intimately woven into cell survival to drug without destroying healthy cells.

Professor Kevan Shokat at UC San Francisco, working with NIH funding, proved this assumption wrong. His team developed the world’s first drugs targeting KRAS mutations—a breakthrough that earned significant attention because it showed that the “undruggable” category exists only until someone finds the right approach. These drugs represent exactly the kind of legacy that cancer gene discoveries create: first you identify the gene, then you understand what it does, then (sometimes years or decades later) you find a way to exploit its weakness. Shokat’s work illustrates that persistence in translating genetic knowledge into therapeutics can succeed even against genes once considered intractable, an insight relevant to many other “difficult” diseases.

Mapping Cancer Gene Mutations: From Data to Prediction

Recent advances show that cancer genetics is moving beyond simply identifying genes to mapping how specific mutations within those genes affect tumor behavior. In February 2026, researchers created the first complete map showing how hundreds of mutations in CTNNB1—a key cancer gene—affect tumor growth. When researchers matched this map against real patient data, the map accurately predicted cancer behavior across different tissue types. This represents a maturation of cancer genetics: from “this gene matters” to “this specific mutation in this gene causes this specific pattern of tumor behavior in patients like you.” For patients and clinicians, this precision matters enormously.

It means that genetic testing can become increasingly granular and predictive. A woman discovered to carry a BRCA1 mutation has different risks and different treatment options than one with a different BRCA mutation in a different part of the gene. The CTNNB1 mapping suggests that within the next decade, genetic information will become increasingly specific to individual mutations rather than simply to genes. However, this also means the medical system must keep pace—genetic counselors, oncologists, and patients must all develop comfort interpreting increasingly detailed genetic information, and insurance systems must adapt to reimbursing tests that are more sophisticated and thus more expensive.

Permanently Silencing Cancer Genes: The Epigenetic Revolution

One of the most striking recent discoveries comes from Monash University and Harvard University researchers who found a way to permanently “switch off” cancer genes in leukemia cells by targeting epigenetic proteins Menin or DOT1L. This approach differs from traditional cancer drugs that kill cancer cells or block their growth—instead, it silences the genes themselves through epigenetic modification. The implication is profound: rather than fighting cancer cells in an endless arms race of drug and resistance, researchers might be able to fundamentally disable the genetic instructions that drive the cancer.

The limitation to understand is that this discovery, while exciting, has so far been demonstrated in leukemia cell models rather than in living patients. The path from cell culture success to clinical drug is long and uncertain. Additionally, cancer cells are adaptable; silencing one gene might activate compensatory pathways. Nevertheless, the approach points toward a future where cancer treatment operates at the level of gene expression itself, manipulating the epigenetic machinery that controls which genes are “on” or “off.” This is conceptually different from how most current cancer drugs work and suggests that the next generation of cancer treatments will increasingly operate at the level that cancer gene discoveries initially revealed.

Permanently Silencing Cancer Genes: The Epigenetic Revolution

The Pancreatic Cancer Resistance Problem: Understanding Therapy Resistance

Pancreatic cancer remains one of the most lethal cancers partly because cancer cells develop resistance to chemotherapy rapidly. In March 2026, researchers identified a key mechanism: the GATA6 gene acts as a molecular switch determining whether pancreatic cancer cells resist or respond to chemotherapy. The mechanism involves overactive KRAS-driven pathways—remember, KRAS is involved in 25% of all cancers—shutting down GATA6 expression. When GATA6 is silenced, the cancer cells become resistant.

Understanding this mechanism creates new opportunities. Rather than giving chemotherapy alone, clinicians might be able to deploy a combination approach: reactivate GATA6 expression (through epigenetic approaches like those discovered by Monash and Harvard) while simultaneously treating with chemotherapy. This example shows how multiple recent cancer gene discoveries feed into each other—KRAS targeting, gene silencing, epigenetic control—to create more sophisticated treatment strategies. It also illustrates why continued investment in understanding cancer genes matters: each discovery about how genes control cancer behavior opens new therapeutic angles.

Building on the Legacy: The Future of Genetic Medicine

Susan Henry’s life and the current acceleration in cancer genetics research illustrate an important principle in science: the best research creates foundations that others build on. Henry did not discover a specific cancer gene, but her work on regulatory circuits—how cells make decisions about growth and metabolism—created conceptual frameworks that informed cancer researchers for decades. The BRCA discoveries, made in the 1990s, continue to generate therapeutic breakthroughs thirty years later through the development of PARP inhibitors and ongoing research into how BRCA mutations affect specific tissues.

The pattern suggests that the cancer genetics discoveries of 2026—CTNNB1 mapping, KRAS drugs, GATA6 mechanisms, gene silencing techniques—will continue rippling outward for decades. Some will lead to treatments quickly. Others will slowly accumulate into new paradigms for how we think about cancer. What ties them all together is the basic insight that cancer is, fundamentally, a disease of genes and cellular regulation—an insight that scientists like Susan Henry helped establish and that continues to drive research forward.

Conclusion

The legacy of scientists who discovered cancer genes extends far beyond the immediate patients they treat. When Mary-Claire King identified BRCA1 in 1990, she could not have predicted that thirty years later PARP inhibitors would be standard treatment, that testing would become routine, or that the “Angelina Jolie Effect” would reshape public awareness of genetic risk. Similarly, Susan Henry’s work on how cells regulate growth and metabolism has rippled through cancer, obesity, and diabetes research, informing the thinking of thousands of scientists who never cited her work directly but applied her principles.

The acceleration of cancer genetics discoveries in 2026—the mapping of CTNNB1, the targeting of KRAS, the silencing of cancer genes, the understanding of GATA6 as a resistance switch—shows that this field is not slowing down. For people interested in brain health and aging, these discoveries matter because the cellular processes that drive cancer also drive aging and neurodegeneration. The regulatory circuits, epigenetic mechanisms, and genetic safeguards that researchers illuminate through cancer studies ultimately inform our understanding of how brains age and how we might protect them. Following your family cancer history, considering genetic testing if indicated by that history, and staying informed as genetic medicine advances are practical ways to engage with this legacy today.